What's Going On With GT Biopharma Stock Tuesday?
What's Going On With GT Biopharma Stock Tuesday?
GT Biopharma (NASDAQ:GTBP) shares rose Tuesday morning before pulling back and turning negative after the company announced a direct offering.
GT Biopharma（納斯達克股票代碼：GTBP）股價週二上午上漲，隨後在公司宣佈直接發行後回落並轉爲負值。
The Details: GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common stock at a purchase price of $4.35 per share. The shares will be offered in a registered direct offering priced at-the-market under Nasdaq rules. Roth Capital Partners is acting as the exclusive placement agent for the offering.
詳情：GT Biopharma簽訂了最終證券購買協議，以每股4.35美元的收購價購買和出售其74萬股普通股。根據納斯達克的規定，這些股票將以註冊直接發行的形式發行，在市場上定價。羅斯資本合夥人是此次發行的獨家配售代理。
In a concurrent private placement, the company announced it will issue warrants allowing the purchase of up to 740,000 shares of its common stock. The warrants will be immediately exercisable at a price of $4.35 per share and will be valid for five years from issuance.
在同時進行的私募中，該公司宣佈將發行認股權證，允許購買多達74萬股普通股。認股權證將立即以每股4.35美元的價格行使，自發行之日起五年內有效。
Before deducting the placement agent's fees and other expenses, the company anticipates raising approximately $3.2 million. GT Biopharma noted that it plans to use the proceeds for general corporate purposes. The offering is expected to close on or about May 23.
在扣除配售代理的費用和其他費用之前，該公司預計將籌集約320萬美元。GT Biopharma指出，它計劃將所得款項用於一般公司用途。此次發行預計將於5月23日左右結束。
Related Link: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
相關鏈接：阿斯利康的目標是通過管道擴張到2030年實現800億美元的總收入
GTBP Price Action: GT Biopharma shares were halted on the circuit breaker Tuesday morning. The stock was down 22.1% at $6.07 at the time of writing, per Benzinga Pro.
GTBP價格走勢：週二上午，GT Biopharma的股票因斷路器而暫停。根據Benzinga Pro的數據，在撰寫本文時，該股下跌了22.1％，至6.07美元。
Image: 761599 from Pixabay.
圖片：來自 Pixabay 的 761599。